Lancet authors push back on claims of neuromodulation underuse in depression care
A short but pointed exchange in depression care has reopened a familiar dispute over how to define, classify, and use brain-based interventions. In a correspondence reply, the authors reject the claim that neuromodulation is being systematically underused and say some of these interventions should be used far less, if at all.
The dispute is not merely semantic. In depression treatment, how an intervention is categorized shapes how clinicians talk about it, how guidelines frame it, and how much weight it carries when treatment-resistant disease becomes the central concern. Here, the authors first set out to correct what they see as confusion over the classification of neuromodulators and electroconvulsive therapy. That distinction matters because the term “neuromodulation” is often used broadly in clinical conversation, even though different interventions have very different mechanisms, indications, and evidence bases.
The response takes direct aim at the idea of underuse. The authors argue that there is no justification for the assertion that neuromodulation interventions are being used too little across depression care. Instead of treating these techniques as a neglected therapeutic class waiting to be deployed more often, they challenge the underlying premise and press for a more selective view of when such interventions deserve a place in practice.
One sentence in the reply carries the clinical position plainly: some of these interventions should be used much less, if at all. In a field where procedural enthusiasm can outpace clear patient benefit, that is a strong reversal of the usual argument. It implies a concern not only about overenthusiastic adoption, but also about whether certain procedures have been granted an unearned therapeutic status simply because they sit under the broad umbrella of neuromodulation.
The exchange also reflects a deeper issue in psychiatry: the gap between technical nomenclature and bedside decision-making. Depression care already asks clinicians to sort among pharmacologic treatment, psychotherapy, somatic procedures, and escalation strategies for severe or refractory disease. When a term such as neuromodulation is applied too loosely, it can blur important differences between interventions that influence neural circuits in entirely different ways. In practical terms, that can distort risk-benefit judgments, patient counseling, and the logic used to justify referrals.
For electroconvulsive therapy, the discussion is especially charged. Electroconvulsive therapy remains one of the most recognizable somatic interventions in psychiatry, and any debate over its proper use inevitably touches on questions of severity, tolerability, and appropriateness. The reply does not offer trial data, new outcomes, or a fresh comparative analysis. Instead, it stakes out a conceptual and clinical position: broad claims of underuse are not persuasive, and enthusiasm for some interventions should be tempered rather than expanded.
Classification is doing real clinical work here
The reply begins by correcting classification, which may sound administrative but is actually central to clinical reasoning. A treatment labeled as neuromodulation enters discussion already carrying assumptions about mechanism and utility. If that label is too broad, then arguments about uptake can become misleading before they even reach the evidence.
Depression treatment often invites this kind of framing problem because severe illness creates pressure to find options when standard care falls short. In that setting, a procedure can quickly acquire a symbolic role as a “next step,” even when the actual evidence supporting broad deployment remains limited, selective, or contested. The authors’ position pushes against that drift and asks readers to separate genuine need from therapeutic momentum.
Their response also suggests that the field should be cautious about reading low utilization as proof of undertreatment. Low use can reflect several realities at once: restrictive indications, burdensome logistics, variable acceptability, uncertain benefit in some populations, or concern about harm. A procedure does not become underused simply because it is less common than its proponents would prefer.
What this means for day-to-day depression care
For clinicians, the practical implication is straightforward even without new trial numbers. The strongest point in the reply is not about expanding access; it is about resisting an assumption that more use is automatically better. When procedures are discussed as if scarcity alone proves neglect, the conversation can drift away from patient selection and toward advocacy.
A more disciplined approach asks whether the intervention improves meaningful outcomes enough to justify its burdens, where it belongs in the treatment sequence, and which patients truly stand to benefit. Those are the questions this correspondence implicitly re-centers. In that sense, the reply is less a technical correction than a warning against therapeutic overgeneralization.
The authors also make clear that the field should not treat all interventions within the neuromodulation family as equivalent. Some may have a justified place in carefully selected patients. Others may not deserve routine use at all. That is a harder position to defend in a culture that often prefers expansion over restraint, but it is also the position most aligned with conservative clinical reasoning.
No new endpoints, cohorts, or safety signals appear in this correspondence. Its value lies in the argument itself: a challenge to the assumption that neuromodulation is broadly underused in depression, a correction to how the interventions are being grouped, and a reminder that some procedures may be too readily accepted as treatment options simply because they are available.
The debate now turns on whether depression care should interpret neuromodulation as an area of unmet need or as a class of interventions that needs tighter boundaries. The correspondence leaves little doubt about where these authors stand, even as it leaves the larger field to sort out how much clinical weight that position will carry.